Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial
- PMID: 9846778
- DOI: 10.1001/jama.280.21.1837
Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial
Abstract
Context: Postherpetic neuralgia (PHN) is a syndrome of often intractable neuropathic pain following herpes zoster (shingles) that eludes effective treatment in many patients.
Objective: To determine the efficacy and safety of the anticonvulsant drug gabapentin in reducing PHN pain.
Design: Multicenter, randomized, double-blind, placebo-controlled, parallel design, 8-week trial conducted from August 1996 through July 1997.
Setting: Sixteen US outpatient clinical centers.
Participants: A total of 229 subjects were randomized.
Intervention: A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo. Treatment was maintained for another 4 weeks at the maximum tolerated dose. Concomitant tricyclic antidepressants and/or narcotics were continued if therapy was stabilized prior to study entry and remained constant throughout the study.
Main outcome measures: The primary efficacy measure was change in the average daily pain score based on an 11-point Likert scale (0, no pain; 10, worst possible pain) from baseline week to the final week of therapy. Secondary measures included average daily sleep scores, Short-Form McGill Pain Questionnaire (SF-MPQ), Subject Global Impression of Change and investigator-rated Clinical Global Impression of Change, Short Form-36 (SF-36) Quality of Life Questionnaire, and Profile of Mood States (POMS). Safety measures included the frequency and severity of adverse events.
Results: One hundred thirteen patients received gabapentin, and 89 (78.8%) completed the study; 116 received placebo, and 95 (81.9%) completed the study. By intent-to-treat analysis, subjects receiving gabapentin had a statistically significant reduction in average daily pain score from 6.3 to 4.2 points compared with a change from 6.5 to 6.0 points in subjects randomized to receive placebo (P<.001). Secondary measures of pain as well as changes in pain and sleep interference showed improvement with gabapentin (P<.001). Many measures within the SF-36 and POMS also significantly favored gabapentin (P< or =.01). Somnolence, dizziness, ataxia, peripheral edema, and infection were all more frequent in the gabapentin group, but withdrawals were comparable in the 2 groups (15 [13.3%] in the gabapentin group vs 11 [9.5%] in the placebo group).
Conclusions: Gabapentin is effective in the treatment of pain and sleep interference associated with PHN. Mood and quality of life also improve with gabapentin therapy.
Comment in
-
Symptomatic treatment of painful neuropathy.JAMA. 1998 Dec 2;280(21):1863-4. doi: 10.1001/jama.280.21.1863. JAMA. 1998. PMID: 9846782 No abstract available.
-
Gabapentin for postherpetic neuralgia.JAMA. 1999 Jul 14;282(2):134-5. doi: 10.1001/jama.282.2.134. JAMA. 1999. PMID: 10411191 No abstract available.
Similar articles
-
Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.JAMA. 1998 Dec 2;280(21):1831-6. doi: 10.1001/jama.280.21.1831. JAMA. 1998. PMID: 9846777 Clinical Trial.
-
Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study.Pain. 2001 Nov;94(2):215-224. doi: 10.1016/S0304-3959(01)00407-9. Pain. 2001. PMID: 11690735 Clinical Trial.
-
The use of gabapentin for the treatment of postherpetic neuralgia.Clin Ther. 2003 Mar;25(3):852-89. doi: 10.1016/s0149-2918(03)80111-x. Clin Ther. 2003. PMID: 12852705 Review.
-
Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia.Am J Geriatr Pharmacother. 2004 Sep;2(3):157-62. doi: 10.1016/j.amjopharm.2004.09.004. Am J Geriatr Pharmacother. 2004. PMID: 15561647
-
Postherpetic neuralgia: role of gabapentin and other treatment modalities.Epilepsia. 1999;40 Suppl 6:S51-6; discussion S73-4. doi: 10.1111/j.1528-1157.1999.tb00933.x. Epilepsia. 1999. PMID: 10530683 Review.
Cited by
-
Combination Drug Therapy for the Management of Chronic Neuropathic Pain.Biomolecules. 2023 Dec 16;13(12):1802. doi: 10.3390/biom13121802. Biomolecules. 2023. PMID: 38136672 Free PMC article. Review.
-
Comparative effectiveness of pain control between opioids and gabapentinoids in older patients with chronic pain.Pain. 2024 Jan 1;165(1):144-152. doi: 10.1097/j.pain.0000000000003006. Epub 2023 Aug 4. Pain. 2024. PMID: 37561652
-
Development of a Patient-Reported Outcome (PRO) Measure to Assess Emotional Impact of Treatment for Type 2 Diabetes.Diabetes Ther. 2023 Sep;14(9):1451-1470. doi: 10.1007/s13300-023-01426-0. Epub 2023 Jun 23. Diabetes Ther. 2023. PMID: 37351820 Free PMC article.
-
The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials.Int J Clin Pharm. 2023 Jun;45(3):556-565. doi: 10.1007/s11096-022-01528-y. Epub 2023 Feb 27. Int J Clin Pharm. 2023. PMID: 36848024 Free PMC article. Review.
-
Feasibility of gabapentin as an intervention for neurorecovery after an acute spinal cord injury: Protocol.Front Neurol. 2022 Nov 7;13:1033386. doi: 10.3389/fneur.2022.1033386. eCollection 2022. Front Neurol. 2022. PMID: 36419530 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical